The trial regimen combined PDS0101, an HPV16 therapeutic peptide cancer vaccine intended to initiate an immune response; PDS01ADC, a tumor-targeting interleukin-12 immunocytokine intended to potentiate that response; and bintrafusp alfa, a bifunctional agent designed to block both programmed cell death ligand 1 (PD-L1) and transforming growth factor beta (TGF-beta). A prior report from trial NCT04287868 described promising clinical activity in patients with advanced HPV16-associated malignancies. The updated analysis examined peripheral immune and serum proteomic measurements in an attempt to identify correlates of clinical response to the combination.

For the proteomic analysis, the investigators surveyed serum proteins and built machine-learning models using data available before therapy or early in the regimen. The reported predictive signals were baseline IL-6 and heme oxygenase 1 concentrations, either used alone or combined with an early change in granzyme B. These models were designed to predict both clinical benefit and the duration of overall survival. Their results show that molecular patterns measured in blood contained outcome-related information in this cohort, but they do not establish that the proteins caused the observed differences in response or survival.

The researchers also conducted a broader survey of the peripheral immunome. Among patients who benefited from treatment, they identified a persistent skewing toward increased ratios of peripheral CD8-positive T cells to myeloid cells. The analysis did not determine whether this cellular pattern produced the better outcomes. It also found a positive association between the frequencies of monocytes and myeloid-derived suppressor cells and serum concentrations of inhibitory biomarkers. According to the authors, that association supplies biological context for the serum-based prediction models by linking measurements of particular circulating cell populations with inhibitory molecular signals.

These findings come from a retrospective study in a cohort of 38 patients with HPV16-positive tumors, and the investigators explicitly called for prospective validation in future clinical studies. The scope of the work was therefore outcome prediction within an already treated trial population, rather than a prospective test of whether clinicians could use serum measurements to select treatment or estimate an individual patient’s survival. The study instead supports further evaluation of minimally invasive molecular measurements obtained before or early in the regimen. Whether the models retain their predictive performance in independent prospective cohorts remains to be determined.

Subject of Research: Serum proteomic prediction of response to combination immunotherapy in advanced HPV16-positive malignancies

Article Title: Baseline and early changes in serum proteomic profiles predict anti-tumor activity in patients with advanced HPV-associated malignancies treated with novel combination immunotherapy

Article References: Goswami, M., Lynch, M. T., Floudas, C. S., Strauss, J., Tsai, Y.-T., Marté, J. L., Gulley, J. L., Schlom, J., & Donahue, R. N. (2026). Baseline and early changes in serum proteomic profiles predict anti-tumor activity in patients with advanced HPV-associated malignancies treated with novel combination immunotherapy. Journal of Experimental & Clinical Cancer Research. https://doi.org/10.1186/s13046-026-03847-8

Image Credits: AI Generated

DOI: 10.1186/s13046-026-03847-8

Keywords: HPV16, cancer immunotherapy, serum proteomics, IL-6, heme oxygenase 1, granzyme B, CD8 T cells, myeloid-derived suppressor cells, bintrafusp alfa, PDS0101, Baseline, early

The investigation focused on the Y402H polymorphism in CFH, a gene whose protein regulates the alternative complement pathway. Individuals homozygous for the risk-associated C allele have previously been reported to have a five- to sevenfold higher risk of AMD than those with the protective TT genotype. The variant lies in a ligand-binding region of factor H and is thought to reduce the protein’s ability to attach to polyanionic surfaces such as Bruch’s membrane. Reduced regulation can permit persistent complement activation and the generation of inflammatory fragments, including C5a. Those fragments can recruit immune cells and stimulate inflammatory responses, but the work reported here asks how a locally active protease might connect complement dysregulation to remodeling of extracellular matrix in the retina and choroid.

To investigate systemic granzyme B concentrations, the researchers examined people with dry AMD and compared them with a younger, non-AMD reference group. Both age-matched AMD genotype groups had higher mean plasma concentrations than the younger controls: 89.49 pg/mL with SEM 23.65 for the CC group and 64.48 pg/mL with SEM 24.35 for the TT group, compared with 22.3 pg/mL with SEM 7.5 in controls. The difference between the two AMD genotypes was not statistically significant in a Mann–Whitney U test. This result did not identify a systemic marker that distinguished the two genotypes, and the comparison does not establish when or where the genotype-associated tissue changes begin. Small sample numbers, including eight participants in each AMD group, limit the strength and generalizability of the plasma comparison, while the age difference between the AMD and control cohorts prevents treating the systemic increase as a genotype-specific effect.

The clearest human findings came from immunofluorescence analysis of non-AMD donor eyes. Five eyes with the high-risk CC genotype were compared with five age-matched protective TT eyes. Choroidal mast-cell density was significantly higher in the CC group, as was the density of mast cells expressing granzyme B. Granzyme B-positive mast cells averaged 4.2 cells per 0.1 square millimeter in CC eyes, compared with 1.9 cells per 0.1 square millimeter in TT eyes. The difference in degranulating mast-cell density only approached the threshold for statistical significance, at p = 0.0635, so the result should not be described as a demonstrated difference in degranulation across the groups. Nevertheless, high-magnification images showed extracellular granzyme B and tryptase granules around a degranulating cell in one CC eye, while dual labeling indicated that 87% of resident choroidal mast cells coexpressed the two proteins. A subset of granzyme B-positive cells, averaging 24.2% when the groups were combined, was tryptase-negative, consistent with other immune sources being present. The tissue evidence therefore supports mast cells as a major local source of granzyme B in this experimental context.

Vitronectin supplied a possible functional link between extracellular granzyme B and complement regulation. An in vitro cleavage assay demonstrated that active granzyme B could generate specific vitronectin fragments after incubation with the protein. In human donor tissue, protective TT eyes displayed strong vitronectin immunoreactivity along Bruch’s membrane and throughout the choriocapillaris and Sattler’s layer, whereas the inner choroid of high-risk CC eyes showed significantly less staining, with a reported p value of 0.0144. CC eyes also more often contained vitronectin concentrated in sub-retinal pigment epithelial deposits, while TT eyes had fewer and smaller deposits consistent with age-related change. The observations indicate redistribution as well as depletion. They are consistent with the proposed model that proteolysis removes soluble or matrix-associated vitronectin while leaving aggregation-prone material near the retinal pigment epithelium, although the tissue study alone cannot prove that granzyme B directly caused the pattern in donors.

The contribution of granzyme B was tested more directly in aged mice. The researchers compared 13- to 17-month-old granzyme B knockout animals with age-matched wild-type C57BL/6 mice, with four animals in each group. Choroidal vitronectin staining was generally faint in wild-type eyes but robust in knockout eyes, particularly around the choriocapillaris and larger choroidal blood vessels. Quantified signal was significantly higher in knockout tissue, at p = 0.0007. This animal comparison supports a role for endogenous granzyme B in regulating or turning over perivascular vitronectin. It does not reproduce the complete human genetic-risk environment, and the knockout establishes the influence of granzyme B on vitronectin abundance more directly than it establishes an AMD phenotype or a treatment effect. The study also does not determine whether elevated granzyme B alone is sufficient to produce the human pattern.

If granzyme B reduces functional vitronectin, complement inhibition should decline and the terminal membrane attack complex should accumulate. The human tissue analysis produced a corresponding pattern. Protective TT eyes had minimal, patchy staining for C5b-9, the membrane attack complex also known as MAC, whereas CC eyes showed prominent deposits around the choriocapillaris and at the interface between Bruch’s membrane and the retinal pigment epithelium. Quantitative analysis confirmed higher MAC immunoreactivity in the high-risk group, with a reported p value of 0.0079. These findings extend previous observations of increased choroidal MAC in high-risk CFH genotypes. Together, the lower vitronectin signal and higher MAC deposition support impaired local complement control, although the cross-sectional donor data cannot establish the temporal order of the two events in an individual eye. The findings also do not show that MAC deposition caused the observed mast-cell infiltration or vitronectin redistribution.

Cell experiments offered a potential explanation for how complement signaling initiates the pathway. Exposure of ARPE-19 retinal pigment epithelial cells to 5 micrograms per milliliter of C5a for 24 hours significantly increased expression of GZMB, TNFα and IL8 messenger RNA, with reported p values of 0.024, 0.0007 and 0.007, respectively. ELISA measurements showed that granzyme B protein remained at similar levels within cell lysates but increased significantly in culture supernatants after stimulation, with a reported p value of 0.0006. The result distinguished increased secretion from increased intracellular storage. C5a-treated cells also showed disruption of the continuous hexagonal pattern of the tight-junction protein ZO-1 after 48 hours, with intracellular accumulation of the protein and fewer cells retaining an intact barrier; the difference in cells displaying intact staining had a reported p value of 0.0037. These findings provide direct experimental evidence that C5a can stimulate granzyme B release and stress RPE cultures. As a simplified culture system, however, ARPE-19 cells do not reproduce the full immune, vascular and extracellular environment of a human eye.

Bulk RNA sequencing of ARPE-19 cells exposed to 100 nanomolar granzyme B for 18 hours identified 1,464 differentially expressed genes. A volcano plot displayed a twofold-change threshold, while a separate greater-than-1.5-fold criterion was applied to the selected epithelial, vascular, barrier, immune, stress and trophic genes shown in the detailed analysis. RPE identity markers RBP1, TJP1 and BEST1 remained stable across control and stimulated groups, but functional enrichment pointed to tissue morphogenesis, epithelial differentiation and vasculature development. Some structural and cell-fate genes increased, including GJA1, PPL, BMP4 and ID3, while CCN2, VEGFA and EDN1 declined. Damage-sensing and stress-associated genes, including TLR3, IL-33 and CYP1B1, increased, while several broad inflammatory or survival cytokines were reduced. The pattern is compatible with attempted barrier compensation alongside diminished vascular and trophic support, but transcriptional signatures alone do not demonstrate retinal atrophy or predict its development in patients.

Collectively, the experiments support a model in which the CFH Y402H risk genotype is linked to chronic complement activation, increased C5a signaling, granzyme B release by RPE cells and infiltrating mast cells, and extracellular remodeling. Cleaved vitronectin may then provide less inhibition of membrane attack complex assembly while contributing to sub-RPE deposits, creating conditions associated with early tissue changes. The study also notes that prior work found granzyme B can cleave C5 to generate active C5a, raising the possibility of a self-reinforcing loop, although that specific feedback mechanism was not directly tested here. Postmortem tissue, limited donor numbers, unequal control ages, the inability to assess biological-sex effects and the reduced fidelity of cell culture and mouse models constrain interpretation. The work identifies extracellular granzyme B as a mechanistic link and a potential therapeutic target, but it does not demonstrate that inhibiting it would prevent AMD or protect vision in patients.

Subject of Research: Granzyme B, vitronectin cleavage and complement dysregulation in early age-related macular degeneration

Article Title: Factor H polymorphism elevates granzyme B and impairs complement inhibition in human and mouse models

Article References: Chakravarthy, H., Xi, J., Yoo, H.-S., Buss, A., Li, B., Bell, R., Haegert, A., Le Bihan, S., Granville, D. J., & Matsubara, J. A. (2026). Factor H polymorphism elevates granzyme B and impairs complement inhibition in human and mouse models. iScience, 29(11), Article 117957. https://doi.org/10.1016/j.isci.2026.117957

Image Credits: AI Generated

DOI: 10.1016/j.isci.2026.117957

Keywords: age-related macular degeneration, CFH Y402H, complement factor H, granzyme B, vitronectin, membrane attack complex, retinal pigment epithelium, choroidal mast cells, extracellular matrix, C5a, Factor, polymorphism

The research, led by Yu Shen and Haibo Shen of the Department of Urology at Xinhua Hospital, Shanghai Jiao Tong University School of Medicine, together with colleagues at Shanghai Jing’an District Central Hospital and the Shanghai Institute of Immunology, set out to resolve a longstanding puzzle. GSDMB is known to be highly expressed in bladder cancer, and previous work had implicated the gasdermin family in anti-tumor immunity, but the precise functional role of GSDMB in shaping the response to immune checkpoint inhibitors had remained unclear. The new study provides what the authors describe as a novel mechanism linking a tumor-intrinsic signaling pathway to the recruitment and activation of cytotoxic immune cells within the tumor microenvironment.

At the heart of the discovery is a signaling axis that the researchers designate as GSDMB–DDX5–Sema7a–CD8+ T cell. According to the study, when GSDMB is overexpressed in bladder cancer cells, it does something unexpected for a protein of its class: it translocates to the nucleus. Once inside the nucleus, GSDMB physically interacts with DEAD-box helicase 5, or DDX5, a well-characterized RNA helicase that participates in the regulation of transcription. Through this interaction, the GSDMB–DDX5 complex upregulates the expression of Semaphorin 7A, or Sema7a, a secreted signaling molecule that the study identifies as the critical downstream effector of the pathway.

Sema7a, once produced by the tumor cells, is secreted into the surrounding tumor microenvironment, where it performs a crucial recruiting function. The researchers demonstrate that secreted Sema7a facilitates the infiltration of CD8+ T cells into the tumor. These cytotoxic T lymphocytes are the principal assassins of the adaptive immune system, capable of recognizing and killing tumor cells directly, and their presence within a tumor, rather than merely around its margins, is one of the strongest predictors of response to immunotherapy. Tumors that are densely infiltrated by CD8+ T cells are often described as immunologically hot, whereas tumors that exclude these cells tend to resist checkpoint inhibitors regardless of how many T cells circulate in the bloodstream.

The study goes further than simply counting infiltrating cells. The researchers found that the CD8+ T cells recruited into GSDMB-expressing tumors were not only more numerous but also more functionally potent. Tumor-infiltrating CD8+ T cells in this setting showed enhanced expression of three hallmark mediators of cytotoxic anti-tumor activity: interferon-gamma, tumor necrosis factor-alpha, and granzyme B. Interferon-gamma and tumor necrosis factor-alpha are inflammatory cytokines that coordinate and amplify immune attacks on tumors, while granzyme B is a serine protease that T cells deliver into target cells to trigger their death. The coordinated elevation of all three molecules indicates that the recruited T cells arrive in an activated, tumor-killing state rather than in an exhausted or suppressed condition.

This mechanism has direct consequences for anti-PD-1 therapy. Immune checkpoint inhibitors such as anti-PD-1 antibodies work by releasing the molecular brakes that tumors place on T cells, but they can only succeed if tumor-reactive T cells are present in the tumor microenvironment in the first place. By promoting the infiltration and activation of CD8+ T cells, GSDMB effectively increases the supply of targetable immune cells, allowing anti-PD-1 treatment to operate on a larger and more vigorous T cell population. The authors report that GSDMB synergizes with the efficacy of immune checkpoint inhibitor therapy in bladder cancer through this promotion of CD8+ T cell infiltration and effector function, establishing the protein as a genuine partner to checkpoint blockade rather than an incidental correlate.

The mechanistic findings are notable because they assign a transcriptional regulatory role to GSDMB, a member of the gasdermin family whose members are classically associated with pyroptosis, a form of inflammatory programmed cell death. The demonstration that GSDMB can move into the nucleus and, through its interaction with the helicase DDX5, drive the transcription of Sema7a expands the known functional repertoire of this protein family. It also reframes gasdermin biology in the context of cancer immunology: rather than acting solely as an executor of cell death, GSDMB in bladder cancer appears to function as a tumor-intrinsic organizer of the immune microenvironment, shaping which immune cells enter the tumor and how aggressively they behave once inside.

Beyond its mechanistic interest, the study carries practical implications for patient care. The authors conclude that GSDMB may serve as a potential prognostic biomarker for outcomes in patients with bladder cancer treated with anti-PD-1 therapy. If validated in larger clinical cohorts, a GSDMB-based test could help oncologists identify, before treatment begins, which patients are likely to respond to checkpoint inhibitors and which might be better served by alternative or combination strategies. This kind of predictive stratification is a pressing unmet need in bladder cancer, where anti-PD-1 agents are used in both metastatic settings and in certain non-muscle-invasive disease contexts, yet response rates vary widely between individuals.

The research also suggests potential therapeutic avenues that extend beyond biomarker development. If the GSDMB–DDX5–Sema7a pathway can be pharmacologically enhanced in tumors with low endogenous GSDMB activity, or if Sema7a itself can be delivered or mimicked to draw CD8+ T cells into immunologically cold tumors, clinicians might one day convert non-responsive bladder cancers into responsive ones. Conversely, the pathway offers a mechanistic explanation for resistance that could be targeted diagnostically: patients whose tumors lack GSDMB expression, and therefore lack the Sema7a-driven recruitment signal, might be candidates for therapies that recruit immune cells through alternative routes, such as oncolytic viruses, cancer vaccines, or chemokine-modulating agents.

The study was conducted with oversight from the Institutional Animal Care and Use Committee of Xinhua Hospital and the hospital’s Ethics Committee, with informed consent obtained from all human participants, and it was supported by grants from the Shanghai Jing’an District Health Commission and the Cross-disciplinary Fund of Xinhua Hospital. Published as an open-access article, the work adds bladder cancer to the growing list of malignancies in which tumor-intrinsic molecular programs are being mapped onto the architecture of the immune microenvironment. As the field of immuno-oncology moves from broad checkpoint blockade toward rational, mechanism-guided combination therapy, findings such as the GSDMB–DDX5–Sema7a axis illustrate how a single tumor protein can orchestrate an entire chain of immune events, from gene transcription in the cancer cell nucleus to the arrival of armed cytotoxic T cells at the tumor front, and how understanding that chain may ultimately determine whether a patient’s immune system can be mobilized to fight back.

Subject of Research: The role of GSDMB in enhancing anti-PD-1 immunotherapy response through Sema7a-mediated CD8+ T cell infiltration in bladder cancer

Article Title: GSDMB synergizes anti-PD-1 efficacy via Sema7a-mediated CD8+ T Cell infiltration in bladder cancer

Article References: Shen, Y., Zhang, S., Yu, S., Chen, K., Li, J., Chen, Z., Ren, T., Liu, H., Xu, D., Wang, Y., & Shen, H. (2026). GSDMB synergizes anti-PD-1 efficacy via Sema7a-mediated CD8+ T Cell infiltration in bladder cancer. Cancer Immunology, Immunotherapy. https://doi.org/10.1007/s00262-026-04597-4

Image Credits: AI Generated

DOI: 10.1007/s00262-026-04597-4

Keywords: bladder cancer, GSDMB, Sema7a, DDX5, CD8+ T cells, anti-PD-1, immune checkpoint inhibitors, immunotherapy, tumor microenvironment, biomarker, granzyme B, interferon-gamma

The scale of the problem is enormous. According to GLOBOCAN 2022 estimates from the International Agency for Research on Cancer, roughly 20 million new cancer cases occur worldwide each year, and solid tumors account for more than 90 percent of them. Lung, breast, colorectal, prostate, and gastric cancers alone make up 45.8 percent of global incidence. Immune checkpoint inhibitors have delivered durable responses in selected solid tumors, while CAR-T therapy remains largely investigational outside blood cancers. Against this backdrop, NK cell-based immunotherapy has attracted attention for its widely recognized low-risk profile and its potential as an off-the-shelf product.

But solid tumor patients are not the same population as hematologic cancer patients. They tend to be older, with lung and gastrointestinal tumors typically appearing at 60 to 70 years of age, and they carry a heavier burden of cardiovascular comorbidities, including hypertension in 26.0 percent, coronary heart disease in 7.8 percent, and heart failure in 3.3 percent. Prior anthracycline chemotherapy or thoracic radiotherapy often leaves the myocardium in a pre-injured state. Because immune checkpoint inhibitors and CAR-T cells can both trigger cardiovascular toxicity through mechanisms such as cytokine release syndrome, the authors argue that as NK cell strategies expand into solid tumors, their cardiac safety must be comprehensively evaluated before clinical translation proceeds.

NK cells kill through a coordinated set of molecular pathways. The activating receptor NKG2D binds stress-induced ligands such as MICA/B and ULBPs on tumor cells, natural cytotoxicity receptors NKp30, NKp44, and NKp46 recognize tumor-specific antigens, and CD16 mediates antibody-dependent cellular cytotoxicity. Once activated, NK cells release perforin and granzymes to punch pores in target-cell membranes, or trigger apoptosis through death ligands such as FasL and TRAIL. They also secrete interferon-gamma and tumor necrosis factor-alpha to recruit dendritic cells and T cells. Crucially, inhibitory receptors such as KIR and NKG2A recognize MHC class I molecules on healthy tissue, generating tolerance and limiting autoimmune injury.

The tumor microenvironment, however, systematically disarms this arsenal. High concentrations of TGF-beta and IDO suppress NK cell activation and proliferation, while nutrient deprivation, hypoxia, and metabolic byproducts such as lactate and adenosine further erode cytotoxic function. Upregulation of HIF-1alpha in solid tumors induces mitochondrial dysfunction in NK cells and inhibits aerobic glycolysis, causing energy-metabolism failure. Tumor-infiltrating NK cells also upregulate inhibitory checkpoints including PD-1, TIM-3, LAG-3, and TIGIT. Single-cell atlases of breast cancer and hepatocellular carcinoma have identified exhausted NK subsets with high expression of NR4A family genes and KLRC1, and these patients tend to have poorer prognoses.

Three therapeutic strategies aim to reverse this exhaustion. Genetic engineering, most notably chimeric antigen receptor NK cells (CAR-NK), equips NK cells with tumor-antigen-specific receptors; genome-wide CRISPR screening has identified negative regulators such as MED12, ARIH2, and CCNC whose knockout enhances metabolic adaptability, and chemokine receptors such as CXCR4 can be introduced to improve tumor infiltration. Antibody-mediated approaches, including bispecific and trispecific immune-cell engagers that bridge tumor antigens and CD16, as well as novel trispecific nanobodies targeting PD-L1, 4-1BB, and NKG2A, have significantly inhibited tumor growth in preclinical models. Cytokine and metabolic regulation, from IL-15 superagonists to intermittent fasting-induced fatty acid oxidation, offers a third route to restoring NK cell fitness.

The advantages of NK cells over T cells are multidimensional. They recognize cells that have lost MHC class I expression, a common consequence of genomic instability in solid tumors, without needing HLA-restricted antigen presentation. Their low risk of graft-versus-host disease and lack of HLA-matching requirements make them candidates for true off-the-shelf products, in contrast to the individualized CAR-T manufacturing process that takes at least three weeks. NK cells can be derived from cord blood, peripheral blood, induced pluripotent stem cells, or immortalized NK-92 cell lines, enabling standardized scaled production. They also rely more on oxidative phosphorylation than glycolysis, giving them better energy efficiency and fatigue resistance in the hostile tumor microenvironment, and their endogenous interferon-gamma can reprogram tumor-associated macrophages from a tumor-promoting M2 phenotype to an antitumor M1 phenotype.

Safety data so far support this optimism. CAR-NK therapy has shown extremely low incidence of cytokine release syndrome and neurotoxicity, with no definitive reports of grade 3 or higher CRS or immune effector cell-associated neurotoxicity syndrome to date. But the review warns that cardiotoxicity is broadly relevant across immunotherapies, and the safety advantages of NK cells should not be mistaken for absence of risk. Immune checkpoint inhibitor-related cardiotoxicity occurs in roughly 1 to 2 percent of patients with a fatality rate of up to 46 percent, significantly higher than myocardial injury from conventional chemotherapy. In CAR-T treatment, cardiovascular adverse events occur in 20.5 percent of patients, with hypotension and tachycardia presenting as hyperacute events within a median of 6 to 21 days.

The mechanisms of immune-mediated cardiac injury offer a preview of what could go wrong with NK cells. Cytokine release directly damages myocardial mitochondria and disrupts calcium homeostasis through IL-6, TNF-alpha, and interferon-gamma, while activating endothelial cells and inducing microvascular obstruction. Alpha-myosin-specific T cells can drive myocarditis, although TCR sequencing suggests most expanded clones target unknown cardiac antigens, challenging the universality of molecular mimicry. A positive-feedback loop between CCR2-positive macrophages and CD8-positive T cells, mediated by the IL-12b/TNF/interferon-gamma axis, remodels the myocardial immune microenvironment, and NLRP3 inflammasome activation triggers gasdermin-E-dependent pyroptosis and release of mitochondrial DNA that activates the cGAS-STING pathway, causing irreversible tissue damage.

For NK cells specifically, several theoretical risks emerge. Although NK cells secrete less IL-6 and IL-1-beta than activated T cells, and their CRS profile is dominated by interferon-gamma, GM-CSF, and TNF-alpha with typically mild grade 1 to 2 manifestations, even mild CRS can trigger capillary leak syndrome, reducing effective circulating blood volume and myocardial perfusion. TNF-alpha downregulates SERCA2a and promotes ventricular remodeling. In mouse models of acute myocardial infarction, mature NK cells massively infiltrate ischemic myocardium through a CCR2-dependent pathway and their granzyme B directly induces cardiomyocyte apoptosis, while granzyme B can also enter vascular smooth muscle cells without perforin assistance. HER2, a common CAR-NK target antigen, has basal expression in normal cardiomyocytes, and although preclinical studies have not shown toxicity against nonmalignant HER2-positive cells, those conclusions rest on short-term in vitro co-culture that cannot simulate the long-term in vivo immune environment.

Engineered persistence introduces further uncertainty. IL-15 and IL-21 both signal through the JAK1/JAK3-STAT5 axis, which in pressure-overload heart failure models directly drives fibroblast activation and type I collagen deposition. Chronic low-grade IL-15 exposure from CAR-NK cells persisting in vivo for several weeks may induce subclinical interstitial remodeling, and IL-15 has been shown to enhance NK cell glycolysis, potentially creating energy competition with cardiomyocytes that depend on oxidative phosphorylation. Combination with PD-1 inhibitors may amplify interferon-gamma-driven cardiomyocyte iNOS expression and nitric oxide production, while prior anthracycline chemotherapy leaves mitochondria leaking reactive oxygen species that can create a second hit when immunotherapy triggers overlapping autoimmune and inflammatory responses.

The knowledge gaps are stark. No prospective, multicenter study dedicated to the cardiovascular safety of NK cell products has yet been conducted; all reports of arrhythmia, heart failure, or myocarditis are scattered across case reports and secondary endpoint analyses. The CTCAE v5.0 grading system classifies events by absolute values alone, overlooking temporal dynamics and recovery trajectories, so subclinical injuries go underreported. Median follow-up in most NK cell trials is less than two years, while delayed cardiomyopathy and immune-mediated vasculitis often manifest years to more than a decade after treatment. Biomarker cutoffs for troponin and NT-proBNP validated in CAR-T contexts have not been established for CAR-NK, and advanced imaging parameters such as cardiac magnetic resonance T1 values and global longitudinal strain have not been formally incorporated into any NK cell trial.

The review proposes a path forward anchored in cardio-oncology collaboration. Baseline risk stratification should integrate the HFA-ICOS score with solid-tumor-specific factors such as chronic hypoxia and malnutrition, and with clonal hematopoiesis of indeterminate potential, an emerging biomarker associated with IL-6-driven endothelial activation after immune stimulation. Dynamic monitoring should combine high-sensitivity troponin, NT-proBNP, electrocardiography, and cardiac magnetic resonance, with baseline ferritin and IL-6 levels included as validated predictors of CRS-related cardiac dysfunction. The microRNA miR-145, negatively correlated with IL-6 and TNF-alpha, deserves evaluation as a diagnostic and potentially cardioprotective marker. For confirmed immune-related myocarditis, pulse methylprednisolone followed by mycophenolate mofetil maintenance is recommended, while tocilizumab should be reserved for CRS-associated cardiac dysfunction to avoid excessive suppression of antitumor immunity.

Deeper cardiovascular monitoring also raises ethical tensions around economic burden, psychological anxiety, and privacy, requiring a balance between scientific rigor and patient wellbeing. Elevating cardiovascular safety to a core dimension of efficacy evaluation could drive developers to optimize NK cell product design at the source. If those gaps are filled, the authors conclude, NK cell-based immunotherapy could become a more efficient, safer, shorter-cycle, and lower-cost option in solid tumor therapy, but only once its cardiac risks move from inference to evidence.

Subject of Research: NK cell-based immunotherapy for solid tumors and its cardiovascular safety

Article Title: Progress in NK cell-based immunotherapy for solid tumors and an exploration of its cardiovascular safety

Article References: Chen, J., Shen, J., Fu, X., Jiang, M., Liu, R., Qiao, Q., & Hu, Y. (2026). Progress in NK cell-based immunotherapy for solid tumors and an exploration of its cardiovascular safety. Frontiers in Cell and Developmental Biology, 14, Article 1927923. https://doi.org/10.3389/fcell.2026.1927923

Image Credits: AI Generated

DOI: 10.3389/fcell.2026.1927923

Keywords: NK cells, CAR-NK, solid tumors, immunotherapy, cardiotoxicity, cytokine release syndrome, tumor microenvironment, immune checkpoint inhibitors, cardio-oncology, granzyme B, IL-15, myocarditis

Vitiligo affects an estimated one percent of the world’s population and is considered a classic model of CD8+ T cell-mediated autoimmunity. In patients with the disease, cytotoxic T cells infiltrate the epidermis and recognize antigens on melanocytes, releasing destructive enzymes and inflammatory signals that eliminate the pigment cells and leave the characteristic white patches on the skin. Current treatments, including topical anti-inflammatory agents and light-based therapies, offer incomplete and inconsistent benefit, and systemic immunosuppressants carry safety concerns that limit their long-term use. Against this backdrop, the research team led by investigators at Xijing Hospital of the Fourth Military Medical University in Xi’an asked a deceptively simple question: could a common food additive alter this destructive immune process?

Sucralose is one of the most widely consumed non-nutritive sweeteners on the planet, found in diet sodas, sugar-free snacks, medications and countless packaged foods marketed as low-sugar alternatives. While it has long been regarded as metabolically inert, recent years have produced accumulating evidence that sucralose is not invisible to the immune system. Earlier work has suggested that the sweetener can influence T cell responses in mice, and epidemiological discussions have raised questions about how high-intensity sweeteners interact with immune homeostasis. What remained unclear was whether sucralose could meaningfully modulate the specific arm of immunity that attacks self-tissue in autoimmune disease, and if so, through what molecular mechanism.

To answer that question, the researchers established a mouse model of vitiligo and administered sucralose orally, mimicking the route by which humans encounter the sweetener. The results were striking. Animals receiving sucralose showed a marked delay in skin depigmentation compared with untreated controls. When the investigators examined the lesions microscopically, they found reduced infiltration of CD8+ T cells into the epidermis and a corresponding preservation of melanocytes, the very cells that are normally lost as the disease progresses. In other words, the sweetener did not merely change laboratory measurements; it visibly slowed the destructive process that defines the disease in living animals.

The team then turned to human cells to determine whether the observation extended beyond mice. They isolated CD8+ T cells from the blood of patients with vitiligo as well as from healthy donors and exposed the cells to sucralose in vitro. Across both groups, the sweetener significantly downregulated the expression of two central mediators of T cell cytotoxicity: interferon-gamma, a potent inflammatory cytokine, and granzyme B, the serine protease that T cells deploy to punch lethal holes in target cells. By suppressing these effector molecules, sucralose effectively reduced the killing capacity of activated CD8+ T cells, the same cells that in vitiligo patients hunt down and destroy melanocytes.

Having established that sucralose dampens T cell effector function, the researchers sought the molecular switch responsible. Using transcriptomic analysis, a technique that profiles the activity of thousands of genes simultaneously, they screened for genes that responded to sucralose exposure in CD8+ T cells. One candidate stood out: interleukin-20 receptor subunit beta, or IL-20RB, a component of a cell-surface receptor belonging to the interleukin-20 cytokine family. In sucralose-treated T cells, IL-20RB was significantly upregulated, suggesting that the sweetener’s effects might be routed through this receptor subunit rather than through a diffuse, nonspecific mechanism.

To test whether IL-20RB was merely a bystander or a genuine mediator of the immunosuppressive effect, the team performed a series of functional validation experiments. When they knocked down IL-20RB expression in CD8+ T cells, the ability of sucralose to inhibit T cell activation was substantially weakened, indicating that the receptor subunit is required for the sweetener’s action. Conversely, when they forced overexpression of IL-20RB in the absence of sucralose, the cells displayed the same immunoregulatory profile that sucralose normally induces. This gain-of-function and loss-of-function symmetry provides strong evidence that IL-20RB sits on the causal pathway: sucralose acts by upregulating IL-20RB, and IL-20RB in turn restrains the activation and effector function of cytotoxic T cells.

The implications of this pathway extend beyond vitiligo. CD8+ T cells are central players in a spectrum of autoimmune diseases, including type 1 diabetes, autoimmune thyroid disease and certain forms of inflammatory skin disease, and they also shape the immune response to tumors, where their cytotoxic function is generally desirable. Any dietary compound that reliably modulates CD8+ T cell activity therefore warrants careful scrutiny in both directions. The authors frame their findings as evidence for a novel diet-responsive immune regulatory pathway and suggest that sucralose, or agents that mimic its effect on IL-20RB, could inspire new dietary or pharmacological strategies for immunomodulation in T cell-mediated autoimmunity.

At the same time, the researchers are explicit about the limits of the current evidence. The study is exploratory, and the authors emphasize that the findings warrant further investigation under physiologically relevant conditions before any conclusions can be drawn about consuming sucralose as a therapeutic strategy. Laboratory models and isolated cells do not capture the full complexity of human metabolism, long-term exposure, dose dependence, or the gut microbiome’s role in processing the sweetener. Notably, the study also assessed a broad panel of safety-related biochemical parameters, including liver enzymes such as alanine aminotransferase and aspartate aminotransferase, bilirubin, alkaline phosphatase, kidney markers including blood urea nitrogen and creatinine, and lipid and glucose measures, reflecting the team’s attention to whether sucralose administration produced systemic toxicity in their model.

For now, the study stands as a provocative example of how everyday food chemistry can intersect with immunology in unexpected ways. It adds sucralose to a growing list of dietary components, from dietary fiber metabolites to salt, whose effects on T cell behavior are far more specific than once assumed. The identification of IL-20RB as a sucralose-responsive gene gives researchers a concrete molecular target to interrogate, one that could potentially be exploited to design safer immunomodulatory interventions for vitiligo and related conditions. Whether the sweetener’s immunosuppressive pathway can be harnessed safely and effectively in patients remains an open question, but the work demonstrates that the boundary between nutrition and immunology is thinner than many imagined, and that the contents of a diet soda may carry immunological consequences that science is only beginning to map.

Subject of Research: Immunomodulatory effects of the artificial sweetener sucralose on CD8+ T cell-mediated autoimmunity in vitiligo

Article Title: Sucralose attenuates CD8+ T cell-mediated autoimmunity via IL-20RB upregulation: implications for dietary immunomodulation in vitiligo

Article References: Xu, Y., Yin, H., Wang, M., Zhu, Q., Wang, X., Guo, W., He, L., Chen, J., Li, S., & Li, C. (2026). Sucralose attenuates CD8+ T cell-mediated autoimmunity via IL-20RB upregulation: implications for dietary immunomodulation in vitiligo. Journal of Translational Medicine. https://doi.org/10.1186/s12967-026-09064-3

Image Credits: AI Generated

DOI: 10.1186/s12967-026-09064-3

Keywords: sucralose, vitiligo, autoimmunity, CD8+ T cells, IL-20RB, interferon-gamma, granzyme B, dietary immunomodulation, artificial sweeteners, melanocytes, Journal of Translational Medicine, T cell activation

Natural killer cells, or NK cells, are the immune system’s rapid-response assassins. Unlike T cells, which must be trained to recognize specific molecular targets, NK cells patrol the body and destroy cells that display telltale signs of stress or malignancy, without prior sensitization. In the liver, however, NK cells often find themselves outmaneuvered. The tumor microenvironment of hepatocellular carcinoma is notoriously immunosuppressive, and exhausted, metabolically starved NK cells frequently lose their ability to produce the toxic arsenal needed to kill cancer cells. Restoring that lost vigor has become a major goal of immunotherapy research, and the new study suggests that a plant-derived compound may help do exactly that.

The investigation began as a screen of Sophora tonkinensis extract, a herb long used in traditional Chinese medicine, against NK-92 cells, a human natural killer cell line widely used in immunology research. Among the active constituents, coumarin stood out for its ability to promote NK cell activation. The team measured cytokine output by enzyme-linked immunosorbent assay, quantified the cytotoxic proteins granzyme B and perforin by western blot and quantitative polymerase chain reaction, and profiled surface receptors by flow cytometry. Crucially, they then repeated the key experiments in primary human NK cells, strengthening the case that the effect is not an artifact of a laboratory-adapted cell line.

The results were striking. Coumarin acted synergistically with interleukin-12, a powerful inflammatory signal that primes NK cells for battle. Together, the two agents pushed NK cells to transcribe, produce, and secrete markedly higher levels of interferon-gamma, the signature cytokine of NK cell activation, along with elevated amounts of granzyme B and perforin, the pore-forming and enzyme-carrying proteins that NK cells use to punch lethal holes in tumor cells. In both NK-92 cells and primary human NK cells, the combination produced a measurable shift toward a more cytotoxic, inflammatory state, suggesting that coumarin could amplify signals that immunotherapies already try to exploit.

To test whether this cellular activation translated into real anti-tumor power, the researchers turned to an H22 hepatocellular carcinoma syngeneic mouse model, in which the animals’ immune systems are intact and able to mount a genuine response against the tumor. Mice treated with coumarin showed significantly reduced tumor volume compared with controls. Flow cytometry of spleen and tumor tissue revealed that the compound increased the infiltration of both NK cells and CD8-positive T cells into the tumor microenvironment, hinting that coumarin does more than simply energize individual cells; it appears to help remodel the immune landscape of the tumor itself, drawing in the very cell types most capable of attacking cancer.

The most technically intriguing part of the study lies in its exploration of metabolism. Transcriptome sequencing of treated NK cells identified 194 upregulated genes and 67 downregulated genes, with the altered genes enriched in energy metabolism pathways. Follow-up Seahorse metabolic analysis, a technique that measures cellular respiration in real time, showed that coumarin significantly increased the oxygen consumption rate of NK cells, a direct indicator of mitochondrial respiratory activity. In other words, the compound appears to restore the energy supply that NK cells need to sustain their demanding killing program, addressing a well-documented vulnerability of NK cells in tumors, where metabolic competition from cancer cells leaves immune cells running on empty.

This metabolic angle connects the findings to a growing body of literature on NK cell bioenergetics. Previous work has shown that mitochondrial fragmentation limits NK cell-based tumor immunosurveillance, and that metabolic fitness is tightly linked to cytotoxic capacity. By boosting oxygen consumption and shifting the transcriptional profile of NK cells toward energy production, coumarin may be recharging the cellular power plants that tumors deliberately drain. The authors are careful, however, to note the limits of the evidence: the current data demonstrate elevated mitochondrial respiratory capacity but do not confirm comprehensive metabolic reprogramming, nor do they identify the direct molecular targets of coumarin within the cell.

That candor matters, because the path from a preclinical observation to a clinical therapy is long and uncertain. Coumarin itself has a complicated pharmacological history; the parent compound is not without toxicity concerns at high doses, and its use as a fragrance agent has been restricted in some contexts. The study also relies on a single syngeneic mouse model, and the effects of IL-12, while potent, have historically been difficult to deploy safely in patients because of systemic inflammatory side effects. Whether coumarin can enhance NK cell function in human tumors at achievable and safe exposures remains an open question that will require pharmacokinetic studies, toxicity testing, and eventually carefully designed clinical trials.

Still, the study adds to a compelling pattern in natural product research. Other plant-derived molecules, including daphnetin, another coumarin-family compound previously identified in screens for NK cell activators, ginsenosides from Panax ginseng, schisandrin C, and various flavonoids, have all shown immunomodulatory effects in recent years. The Chengdu University of Traditional Chinese Medicine and Chinese PLA General Hospital team, whose work was supported by the National Natural Science Foundation of China and other national and Beijing research programs, has previously explored how botanical compounds modulate innate immune pathways such as cGAS-STING. The new findings extend that program into NK cell biology and tumor immunotherapy, suggesting that traditional medicine libraries remain a rich source of immune-active chemistry.

For hepatocellular carcinoma patients, the stakes are high. Liver cancer is a leading cause of cancer death worldwide, and while immune checkpoint inhibitors and tyrosine kinase inhibitors have improved outcomes in recent years, many patients do not respond or eventually relapse. Approaches that boost innate immunity, particularly NK cell function, represent an attractive complementary strategy, and the idea that a well-characterized small molecule could potentiate existing cytokine signals is appealing from both a cost and a combinability standpoint. The authors conclude that coumarin serves as a promising preclinical natural product candidate for liver cancer immunotherapy, one that inhibits tumor growth by improving NK cell cytotoxic function, remodeling the tumor immune microenvironment, and enhancing mitochondrial bioenergetic activity. If follow-up studies can pin down the direct molecular target of coumarin and validate the effect in additional models, this fragrant old molecule may yet earn a new role in the modern immunotherapy arsenal.

Subject of Research: Coumarin-mediated activation of NK cells as a potential immunotherapy mechanism against hepatocellular carcinoma

Article Title: Mechanism of Coumarin in the anti-liver cancer activity by promoting NK cell activation

Article References: Wen, J., Guo, Y., Wang, X., Xu, Y., Lu, Z., Liu, Q., Zhan, X., Xiao, X., & Bai, Z. (2026). Mechanism of Coumarin in the anti-liver cancer activity by promoting NK cell activation. Medical Oncology, 43(11), Article 306. https://doi.org/10.1007/s12032-026-03413-4

Image Credits: AI Generated

DOI: 10.1007/s12032-026-03413-4

Keywords: coumarin, natural killer cells, hepatocellular carcinoma, liver cancer, immunotherapy, interleukin-12, interferon-gamma, granzyme B, perforin, mitochondrial metabolism, Sophora tonkinensis, tumor microenvironment

The rationale behind the study rests on a strategy that has gained considerable traction in oncology: drug repurposing. Bringing a brand-new molecule from discovery to the clinic can take well over a decade and cost more than a billion dollars, whereas established drugs come with known safety profiles, manufacturing routes, and, in some cases, prior human exposure data. Clofoctol, an antibiotic with a long clinical history in parts of Europe, had already attracted attention for direct antitumor activity in preclinical studies. What remained poorly understood—and what motivated the Beijing team led by Yue Wang, Wei Han, and Xiaozhong Peng—was whether the drug could also act on the immune landscape of glioblastoma, a tumor whose microenvironment is famously hostile to infiltrating lymphocytes.

To probe that question, the researchers turned to an orthotopic GL261 model, in which glioblastoma cells are implanted directly into the brains of immunocompetent mice. This model is widely regarded as one of the most faithful experimental systems for glioblastoma immunology because it preserves an intact blood-brain barrier and an intact immune system, both of which are essential when the question at hand concerns systemic immune trafficking. Using flow cytometry, the team compared the immune composition of tumors from clofoctol-treated animals against controls, and the differences were striking. Tumors from treated mice contained a substantially higher proportion of CD8-positive cytotoxic T cells—the immune system’s primary tumor-killing operatives—and those cells expressed elevated levels of cytotoxic effector molecules, hallmarks of a tumor microenvironment shifting from immunologically cold to immunologically active.

Perhaps the most intriguing finding, however, lay outside the tumor itself. When the researchers analyzed the composition of cells in the bone marrow, they observed that glioblastoma was associated with an accumulation of T cells sequestered in that compartment, a phenomenon consistent with the systemic T-cell dysfunction that increasingly is recognized as a barrier to immunotherapy in brain tumors. Clofoctol treatment partially relieved this sequestration, promoting a redistribution of T cells back into systemic circulation and, ultimately, into the tumor. In other words, the drug appears to work not only within the tumor microenvironment but at the level of whole-body immune architecture, releasing a reservoir of cytotoxic lymphocytes that the tumor had effectively locked away.

The causal importance of CD8-positive T cells to the therapeutic effect was confirmed in a depletion experiment. When the researchers eliminated CD8-positive T cells from the animals, the antitumor efficacy of clofoctol was markedly attenuated. That result matters because it elevates the drug from a possible bystander to a demonstrably T-cell-dependent intervention: whatever else clofoctol may be doing to tumor cells directly, its benefit in this model hinges on the presence of a functional cytotoxic T-cell population. For a field in which many repurposed drugs show antitumor effects that turn out to be independent of immunity—and therefore unlikely to synergize with checkpoint blockade—this distinction is critical.

In vitro co-culture experiments added a second layer of mechanistic support. When CD8-positive T cells were pretreated with clofoctol and then exposed to target cells, their cytotoxic activity increased, accompanied by upregulated expression of granzyme B, perforin, and interferon-gamma—the molecular arsenal that cytotoxic lymphocytes use to punch holes in target-cell membranes and trigger programmed cell death, along with the inflammatory cytokine that amplifies antitumor immune signaling. The drug, in short, did not merely deliver more T cells to the tumor; it made the T cells that arrived more lethal.

To trace the signaling pathway behind this activation, the team employed an affinity-based chemoproteomic approach known as ITSA-MS, which screens for proteins that bind a drug of interest in cellular lysates. That screen identified BCL9, a scaffolding protein best known for its role in Wnt signaling and previously implicated in various cancers, as a candidate clofoctol-responsive protein. Subsequent western blot analyses revealed that clofoctol treatment was associated with increased phosphorylation of VAV1, AKT, and ERK—a cascade of signaling events well established in T-cell activation, in which VAV1 relays receptor proximal signals downstream to AKT and ERK pathways that drive proliferation, survival, and effector differentiation. The authors are careful to note that the precise regulatory relationship between BCL9 and this phosphorylation cascade remains to be worked out, but the convergence of chemoproteomic and biochemical evidence points to a coherent mechanism by which the antibiotic potentiates T-cell function.

The translational payoff came in the combination experiments. Glioblastoma’s failure to respond to PD-1 blockade is thought to stem from multiple converging deficits: a physically and immunologically protected location behind the blood-brain barrier, a profoundly immunosuppressive microenvironment, and a systemic T-cell compartment that is itself dysfunctional. Checkpoint inhibitors address only one link in that chain—releasing the molecular brakes on T cells—but they cannot help if there are too few functional T cells reaching the tumor in the first place. Clofoctol, according to the new data, addresses complementary links in the chain by mobilizing T cells from the bone marrow and sharpening their cytotoxic program. When the researchers combined clofoctol with an anti-PD-1 antibody, the treated animals showed greater intratumoral CD8-positive T cell abundance and effector activity, tighter tumor control, and significantly prolonged survival compared with either monotherapy.

The implications extend beyond glioblastoma itself. The finding that a systemically administered, clinically familiar small molecule can redistribute T cells from a bone marrow reservoir and enhance their killing capacity suggests a generalizable strategy for tumors characterized by T-cell sequestration and exhaustion. It also adds to a growing appreciation that the bone marrow acts as a dynamic immunological compartment in cancer, one that can be therapeutically targeted rather than simply observed. If the mechanisms hold up in further studies, clofoctol-like approaches could complement checkpoint blockade in other poorly immunotherapy-responsive cancers, where the limiting factor is not T-cell priming but T-cell delivery and function.

Considerable caution is nonetheless warranted before extrapolating to patients. The findings derive from a single murine model, and glioblastoma models have a well-documented history of promising immunotherapy results that failed to translate into human benefit. The authors themselves emphasize that the link between BCL9 and the observed signaling changes requires further investigation, and the dosing, safety, and pharmacokinetic questions specific to combining an antibiotic with checkpoint inhibitors in the setting of brain tumors remain open. Still, the study exemplifies the promise of drug repurposing viewed through an immunological lens: an old molecule, examined with modern flow cytometry, chemoproteomics, and combination-design thinking, reveals an unexpected capacity to reorganize the immune system in ways that make immunotherapy work better. For a disease whose median survival has barely moved in decades, that is a direction worth pursuing with urgency.

Subject of Research: Repurposing the antibiotic clofoctol to enhance T-cell-mediated immunotherapy response in glioblastoma

Article Title: Clofoctol promotes systemic T-cell redistribution and intratumoral cytotoxicity to improve the response to PD-1 blockade in glioblastoma

Article References: Wang, Y., Li, E., Ai, C., Zhang, Y., Yin, B., Hou, L., Han, W., & Peng, X. (2026). Clofoctol promotes systemic T-cell redistribution and intratumoral cytotoxicity to improve the response to PD-1 blockade in glioblastoma. Cancer Immunology, Immunotherapy. https://doi.org/10.1007/s00262-026-04544-3

Image Credits: AI Generated

DOI: 10.1007/s00262-026-04544-3

Keywords: glioblastoma, clofoctol, drug repurposing, immunotherapy, PD-1 blockade, CD8-positive T cells, bone marrow, tumor microenvironment, BCL9, granzyme B, immune checkpoint blockade, Cancer Immunology Immunotherapy

The inspiration comes directly from living cells. Biological ion channels are not rigid sieves; they are dynamic molecular machines that couple their local electrostatic environment to the hydration state of the interface, achieving selectivity and transport rates that approach the diffusion limit. Potassium channels, for example, use coordinated amino acid residues to strip the hydration shell from ions as they pass. Synthetic solid-state nanochannels have long tried to imitate this behavior by decorating rigid channel walls with stimuli-responsive molecules, converting molecular recognition events directly into measurable ionic currents. The problem has always been that these functionalizations are essentially two-dimensional, painting the sensing chemistry onto a flat surface where physiological salt can neutralize it.

The new platform, developed by Liu Shi, Genxi Li and colleagues, flips that geometry. Instead of modifying the channel surface, the team assembled a peptide-DNA hybrid hydrogel asymmetrically on the exterior of an anodic aluminum oxide membrane, creating a volumetric functional zone roughly 25 to 30 micrometers thick that acts as an active ion trap. The hydrogel is superhydrophilic and densely charged, so it pre-concentrates bulk ions through macroscopic Donnan enrichment while simultaneously generating a substantial Donnan potential. Because this charge reservoir occupies a volume orders of magnitude larger than the compressed Debye length, it keeps working even in the harshest ionic environments the body can supply.

The molecular architecture of the gate is a piece of careful supramolecular engineering. Single-stranded linker DNA is covalently anchored to the nanochannel surface, then a bridging strand and polyacrylamide conjugates are hybridized stepwise into the network. At the heart of the assembly sits a peptide-DNA complex cross-linker, synthesized through orthogonal thiol-maleimide coupling and strain-promoted alkyne-azide cycloaddition. The peptide backbone physically tethers the polymer-nucleic acid strands in close proximity, and this localized proximity effect entropically stabilizes the short DNA duplexes that hold the whole gel together. The elegance of the design is that the same tether that builds the network becomes its Achilles heel: a specific enzyme can cut it, and the entire structure falls apart on command.

That enzyme is Granzyme B, a serine protease released by cytotoxic T lymphocytes and a pivotal biomarker for gauging whether lung cancer patients are responding to immune checkpoint blockade therapy. When Granzyme B cleaves the peptide cross-linkers, the hydrogel undergoes a macroscopic gel-to-sol phase transition. Rheological measurements captured the collapse dramatically, with the storage modulus falling below the loss modulus as the elastic network vanished. Confocal microscopy showed fluorescently labeled gels fading after enzymatic treatment, while spectroscopy confirmed the loss of amide and hydrogen-bonding signatures. The gate does not merely weaken; it switches off.

The shutdown is synergistic, and that synergy is where the signal amplification comes from. As the gel disassembles, its volumetric charge reservoir dissipates, with the effective surface charge density dropping from -5.26 to -0.92 millivolts per square centimeter, an 82.5 percent loss in charge capacity. At the same time, the interface loses its superhydrophilicity, with the water contact angle rising from about 7.6 degrees to 39.0 degrees. Finite-element simulations governed by the Poisson-Nernst-Planck equations, fed with these experimentally measured parameters, showed the cation enrichment zone vanishing and the energy barrier for ion entry soaring. In a two-compartment electrochemical cell, the device swung from a high-current ON state of roughly 17.8 microamperes to an OFF state of about 3.07 microamperes, a gating ratio of approximately 5.8.

The comparison with a conventional two-dimensional control is what makes the result compelling. A monolayer of the same peptide chemistry on the channel surface showed only minor changes in wettability and charge after cleavage, and its sensing performance suffered accordingly, with a constrained dynamic range and reduced linearity. More tellingly, when the researchers varied the background ionic strength from 10 to 200 millimolar, the 2D device’s gating ratio collapsed sharply around 50 millimolar, exactly where Debye screening takes over. The 3D hydrogel platform, by contrast, maintained robust signal modulation all the way to 200 millimolar. In a physiological 150 millimolar buffer, the device still achieved a limit of detection of 133.60 femtomolar, while in low-salt conditions it reached an extraordinary 0.830 femtomolar across a range spanning six orders of magnitude.

The modularity of the building blocks opened a further, almost playful dimension: molecular computing. By incorporating cross-linkers responsive to both Granzyme B and matrix metalloproteinase 2 into a single hydrogel, the team built a cascaded logic circuit with two parallel INHIBIT sub-circuits feeding an OR gate. Each enzyme can independently trigger the phase disassembly and generate a current response, but a specific inhibitor for each enzyme vetoes the process. The device executed a full truth table of Boolean operations on biochemical inputs, supported by molecular docking simulations of the enzyme-inhibitor pairs. It is a small demonstration, but it points toward sensors that do not merely detect a molecule but compute a diagnosis from a panel of interacting biological signals.

Robustness in messy biological fluids proved equally impressive. The intact hydrogel doubles as a physical shield against non-specific fouling, and the sensor held its performance in 10 percent fetal bovine serum and 10 percent human serum, showing strict selectivity against a panel of interfering proteins. The device survived five regeneration cycles with consistent current switching, showed negligible degradation over 15 days of storage, and achieved batch-to-batch reproducibility with a relative standard deviation of just 1.62 percent. These are the unglamorous metrics that decide whether a laboratory curiosity can ever become a clinical instrument, and the platform passed them.

The clinical proof of concept is the most striking part of the story. Working with serum samples from healthy donors and lung cancer patients collected before and after immune checkpoint blockade therapy, under a protocol approved by the Medical Ethics Committee of Shanghai Pulmonary Hospital, the team measured Granzyme B directly in unpurified specimens. Healthy individuals averaged around 0.8 picomolar, while pre-treatment patients showed suppressed levels of roughly 0.3 to 0.5 picomolar, reflecting the immunosuppressive microenvironment of advanced malignancies. After immunotherapy, concentrations surged to 2.0 to 2.5 picomolar, signaling restored T-cell cytotoxicity. Benchmarked against a commercial ELISA, the sensor achieved a correlation coefficient of 0.962, a negligible mean bias of 0.0423 picomolar by Bland-Altman analysis, and an area under the ROC curve of 0.980 for distinguishing healthy from pre-treatment patients, with near-perfect discrimination of therapeutic response. The researchers acknowledge that translation will require packing the electrochemistry into automated microfluidic cassettes and expanding the logic gates to wider biomarker panels, but the core demonstration stands: by thinking in three dimensions, a dissolving gel has done what flat chemistry could not, carrying ultrasensitive nanochannel sensing out of the buffer and into the blood.

Subject of Research: A three-dimensional hydrogel soft-gating strategy for solid-state nanochannel biosensors that circumvents Debye screening to enable ultrasensitive detection of Granzyme B for immunotherapy monitoring.

Article Title: Hydrogel Phase Transition‐Driven Soft Gating Circumvents Debye Screening for Advanced Biosensing

Article References: Shi, L., Zhang, Z., Li, B., Gao, Y., Zhang, R., Mu, Z., Ni, J., Bo, B., & Li, G. (2026). Hydrogel Phase Transition‐Driven Soft Gating Circumvents Debye Screening for Advanced Biosensing. Advanced Science, Article e78049. https://doi.org/10.1002/advs.78049

Image Credits: AI Generated

DOI: 10.1002/advs.78049

Keywords: nanochannel biosensing, hydrogel, Debye screening, Donnan enrichment, Granzyme B, peptide-DNA hybrid, iontronics, immune checkpoint blockade, lung cancer, biocomputing, phase transition, clinical diagnostics

The trick lies in a class of receptors known as TCR-like CARs. Unlike conventional CARs, which bind surface proteins directly, TCR-like receptors are designed to mimic the specificity of T-cell receptors: they recognize short peptide fragments derived from intracellular proteins that are chopped up, shuttled to the cell surface, and displayed on human leukocyte antigen molecules. This presentation system turns the interior of the cell into a display window. If a tumor cell produces an abnormal or abnormally abundant protein, fragments of that protein end up on the surface as peptide-HLA complexes, even though the intact protein itself never leaves the cell. Antibody-based CARs cannot see these complexes; TCR-like CARs can.

The Brazilian team, led by corresponding author Virginia Picanço-Castro together with first author Sima Ebrahimabadi and colleagues, chose to target the cancer-testis antigen MAGE-A4, an intracellular protein that is normally silent in adult tissues except for the testis, which is immunologically privileged, but is re-expressed at high levels in a range of malignancies, including melanoma, sarcoma, and multiple myeloma. Their CAR was built to recognize a specific MAGE-A4-derived peptide presented by the HLA-A*02:01 molecule, one of the most common HLA types in human populations. The construct incorporated CD3ζ, the canonical activation domain used in CAR design, paired with an intracellular signaling domain derived from GITR, a co-stimulatory receptor known to bolster T-cell and NK-cell function.

What makes the study distinctive is its choice of effector cell. Most CAR therapy research has focused on T cells, but natural killer cells offer several practical advantages. NK cells can be harvested from healthy donors and used in an allogeneic setting without triggering graft-versus-host disease, they carry their own arsenal of activating and inhibitory receptors that can be harnessed for additional tumor recognition, and they do not persist indefinitely in the patient, which may limit long-term toxicity. The researchers evaluated their MAGE-A4 CAR in two platforms: the NK-92 cell line, a well-established laboratory model for NK-cell engineering, and primary peripheral blood NK cells isolated from healthy donors, which better approximate the product that would eventually reach patients.

One of the most striking findings came from metabolic profiling of the engineered NK-92 cells. CAR expression did not simply arm the cells with a new recognition capability; it fundamentally improved their energetic condition. The CAR-positive cells showed increased glycolysis, elevated basal respiration, and greater ATP production compared with unmodified controls. Metabolic fitness is increasingly recognized as a critical determinant of whether immune cells can sustain their attack inside the hostile, nutrient-poor environment of a solid tumor, where oxygen is scarce and glucose is contested. By demonstrating that TCR-like CAR expression enhances the metabolic engine of NK cells, the study adds a dimension to CAR design that goes beyond simple target recognition.

Functionally, the engineered cells proved far more lethal to tumor targets than their unmodified counterparts. When exposed to MAGE-A4-positive cell lines—the melanoma line A375, the osteosarcoma line U2OS, and the multiple myeloma line U266—the CAR-NK cells killed significantly more tumor cells. Crucially, they left the MAGE-A4-negative colorectal cancer line HCT116 largely untouched, confirming that the killing was antigen-specific rather than a nonspecific boost in aggression. The enhanced cytotoxicity was accompanied by measurable changes in the machinery of cell killing: the CAR-NK cells showed increased CD107a degranulation, a marker of lytic granule release, along with elevated expression of granzyme B and perforin, the two pore-forming and enzyme-mediated weapons NK cells use to dismantle target cells from within.

The inflammatory output of the engineered cells also rose. CAR-NK cells produced higher levels of the cytokines TNF-α and IFN-γ upon encountering MAGE-A4-positive targets. These signaling molecules do more than reflect activation; they recruit and shape the broader immune response within the tumor microenvironment, potentially converting a localized cell-killing event into a wider immunological alarm. The same pattern of enhanced killing and cytokine secretion was reproduced in primary NK cells carrying the CAR, an important validation step, since laboratory cell lines sometimes behave very differently from the primary cells that would be used clinically.

The decisive test came in vivo. The researchers implanted A375 human melanoma cells into immunodeficient mice and treated them with the MAGE-A4 CAR NK-92 cells. The engineered cells demonstrated potent antitumor activity, controlling the xenografted tumors in a way that unmodified NK-92 cells could not. Xenograft models have well-known limitations—they lack a complete human immune system, and tumor biology in mice does not perfectly mirror human disease—but they remain an essential preclinical gate. Passing that gate means the therapy has shown it can function not just in a culture dish, where nutrients and oxygen are abundant and targets are easily reached, but inside a living organism where cells must traffic, survive, and kill under physiological pressure.

The work, published in Cancer Immunology, Immunotherapy, arrives amid growing enthusiasm for MAGE-A4 as a target in cellular immunotherapy. T-cell receptor therapies directed at MAGE-A4 have already entered clinical trials for sarcoma and other solid tumors, and the antigen’s restricted expression pattern makes it one of the safer intracellular targets currently under investigation. Extending that targeting logic to NK cells, and combining it with co-stimulatory signaling through GITR, offers a potentially off-the-shelf alternative that could be manufactured from donor blood and administered without the individualized production timelines that autologous T-cell therapies require. The authors note that their findings collectively demonstrate that TCR-like targeting of MAGE-A4 using CAR-engineered NK cells enhances metabolic fitness, effector function, and antitumor activity, positioning the approach as a promising immunotherapeutic strategy for MAGE-A4-positive solid tumors.

Considerable work remains before such a therapy could reach patients. The study was conducted in cell lines and xenograft models, and questions about persistence, trafficking to dense solid tumor masses, and behavior in the presence of a full human immune system will need answers in more sophisticated models and, eventually, clinical trials. HLA restriction also means the therapy would apply only to patients carrying HLA-A*02:01, narrowing the eligible population, though that allele is common enough to make the approach broadly relevant. Tumor heterogeneity poses another challenge: cancers that downregulate MAGE-A4 or lose HLA expression could escape recognition, a known vulnerability of all peptide-HLA-directed strategies. Even so, the convergence of metabolic enhancement, antigen specificity, and in vivo efficacy reported here gives researchers a concrete template for engineering NK cells against the hidden interior world of the cancer cell, a world that conventional antibody-based therapies have never been able to reach.

Subject of Research: TCR-like CAR-engineered NK cells targeting the MAGE-A4/HLA-A*02:01 peptide-HLA complex for solid tumor immunotherapy.

Article Title: TCR-like MAGE-A4/HLA-A*02:01 CAR-NK cells enhance antitumor effector function and control melanoma xenografts

Article References: Ebrahimabadi, S., Schmidt, D., Cariati Tirapelle, M., dos Santos, M. H., Fonseca Lima, L. R., Biggi, A. F., Melo Garcia Ferreira, C., da Silva-Januário, M. E., Tocantins Calado, R., & Picanço-Castro, V. (2026). TCR-like MAGE-A4/HLA-A*02:01 CAR-NK cells enhance antitumor effector function and control melanoma xenografts. Cancer Immunology, Immunotherapy. https://doi.org/10.1007/s00262-026-04551-4

Image Credits: AI Generated

DOI: 10.1007/s00262-026-04551-4

Keywords: chimeric antigen receptor, natural killer cells, TCR-like CAR, MAGE-A4, HLA-A*02:01, solid tumor, melanoma, immunotherapy, metabolic fitness, xenograft model, granzyme B, GITR signaling

Non-tuberculous mycobacteria, often abbreviated NTM, are environmental organisms that increasingly cause chronic and debilitating lung disease worldwide. Among them, Mycobacterium abscessus stands out as particularly menacing. It is naturally resistant to many standard antibiotics, it can form ropelike cords that shield it from engulfment by immune cells, and it thrives in patients with pre-existing lung damage such as bronchiectasis, cystic fibrosis, or pulmonary fibrosis. Treatment regimens typically stretch for many months, involve multiple toxic drugs, and frequently fail to eradicate the infection. Against this grim clinical backdrop, the question of how the immune system naturally fights M. abscessus has remained surprisingly underexplored, particularly with respect to γδ T cells, an unconventional lymphocyte population whose role in NTM infection had never been systematically characterized.

γδ T cells differ from the conventional αβ T cells that dominate textbook immunology. Rather than recognizing peptide fragments presented by major histocompatibility molecules, they respond rapidly to a wide range of stress signals and microbial products, earning them a reputation as a bridge between innate and adaptive immunity. A major subset of these cells produces interleukin-17A, a powerful inflammatory cytokine best known for recruiting neutrophils and shaping defenses at body surfaces. To determine whether these cells matter in M. abscessus infection, the researchers built a mouse model of pulmonary infection and mapped the immune landscape of lung tissue over the early days of disease using single-cell RNA sequencing, a technique that captures the gene expression profile of thousands of individual cells simultaneously.

The single-cell atlas revealed a striking pattern. As infection took hold, γδ T cells accumulated in the lung and expanded a population that expressed high levels of IL-17A. When the team removed γδ T cells entirely, using mice genetically engineered to lack them, the consequences were dramatic: bacteria persisted at far higher levels in the lungs and spleens, and lung inflammation worsened. Conversely, when γδ T cells were depleted in animals that had already cleared a first infection and were then re-challenged, the protective advantage of prior exposure evaporated. These experiments established γδ T cells as indispensable players in the early defense against M. abscessus, a finding that had not been demonstrated before for any non-tuberculous mycobacterial pathogen.

Delving deeper, the investigators identified IL-17A itself as the linchpin of this protective response. Mice unable to produce IL-17A lost much of their capacity to control the infection, and importantly, the defect traced back to the γδ T cells themselves. Without IL-17A signaling, the cells became less adept at recognizing the bacterium and lost much of their cytotoxic firepower. In an elegant series of transfer experiments, IL-17A-deficient γδ T cells failed to protect infected animals, whereas their normal counterparts succeeded. This revealed something unusual: IL-17A was not merely acting as a broadcast signal to other immune players but was required within the γδ T cells themselves, a cell-intrinsic requirement that underscores how tightly the cytokine and its producer are wired together during this infection.

The mechanism by which these cells actually kill the bacterium proved to be equally instructive. M. abscessus is an extracellular pathogen during key phases of infection, residing outside host cells in the airways and tissue spaces. The researchers found that IL-17A-positive γδ T cells eliminated extracellular bacteria through a granzyme B-dependent cytotoxic pathway. Granzyme B is a serine protease classically associated with the destruction of virus-infected or malignant cells, delivered through pore-forming perforin or other release mechanisms. Its deployment against free-living bacteria adds a new dimension to the antimicrobial portfolio of γδ T cells and explains how a lymphocyte population usually discussed in the context of autoimmunity and inflammation can act as a direct bactericidal weapon.

How, then, does the immune system know to mobilize these cells in the first place? The answer lies in a cascade that begins with Toll-like receptor 2, a pattern-recognition receptor on macrophages that detects components of the bacterial cell wall. When M. abscessus engaged TLR2 on lung macrophages, the macrophages responded by secreting two cytokines, interleukin-1β and interleukin-23. This cytokine pair is a well-known stimulus for IL-17 production in T cells, and in this context it drove both the expansion and the activation of the IL-17A-positive γδ T cell population. Blocking either IL-1β or IL-23 in infected mice diminished the γδ T cell response and impaired bacterial control, mapping out a complete signaling axis that runs from bacterial recognition through macrophage activation to lymphocyte mobilization and, ultimately, bacterial killing.

Perhaps the most clinically resonant aspect of the study concerns patients whose immunity depends on interferon-gamma, the canonical cytokine for defense against mycobacteria. A subset of individuals, particularly in Southeast Asia, develops autoantibodies that neutralize their own interferon-gamma, leaving them exquisitely vulnerable to disseminated NTM infections. Using single-cell RNA sequencing of peripheral blood cells from NTM patients, the researchers found evidence that anti-interferon-gamma autoantibodies compromise γδ T cell function in humans, mirroring what they observed in mice lacking the interferon-gamma receptor. Crucially, in mice engineered without functional interferon-gamma signaling, IL-17A-positive γδ T cells still conferred protection, and the same held true in a model combining M. abscessus infection with bleomycin-induced pulmonary fibrosis. In other words, this arm of immunity operates independently of the interferon-gamma axis and remains effective even in scarred, damaged lungs.

The implications for therapy are considerable. Current treatment of NTM disease relies almost entirely on antibiotics that the pathogen is adept at resisting, and there are no licensed immunotherapies that bolster host defenses. If the pathways defined in this study can be harnessed in patients, whether by stimulating IL-1β and IL-23 signaling, expanding protective γδ T cell populations, or delivering IL-17A-driven cytotoxic activity directly, clinicians could gain a means of strengthening the lung’s own antimicrobial machinery. Such approaches would be especially valuable for the growing population of patients with anti-interferon-gamma autoantibodies or structural lung disease, for whom conventional regimens offer diminishing returns. The researchers caution that translating mouse findings to the clinic will require careful work, particularly because IL-17A is also implicated in inflammatory conditions such as psoriasis and could carry safety risks if induced systemically. Nevertheless, the identification of a concrete, mechanistically defined cell type that can clear M. abscessus marks a genuine advance. It transforms γδ T cells from immunological bystanders into a promising therapeutic target, and it reframes the fight against antibiotic-resistant mycobacteria as a battle that the immune system, with the right encouragement, may be able to win on its own terms.

Subject of Research: The role of IL-17A-producing γδ T cells in controlling pulmonary Mycobacterium abscessus infection in mice.

Article Title: IL-17A-producing γδ T cells control pulmonary Mycobacterium abscessus infection in mice

Article References: Hu, X., Lin, S., Meng, W., Liu, H., Qin, Z., Wu, Z., Wan, Y., Ma, S., Yang, X., Yin, Z., Chu, Y., Zhang, W., Shao, L., & Lin, Y. (2026). IL-17A-producing γδ T cells control pulmonary Mycobacterium abscessus infection in mice. Nature Microbiology. https://doi.org/10.1038/s41564-026-02466-5

Image Credits: AI Generated

DOI: 10.1038/s41564-026-02466-5

Keywords: Mycobacterium abscessus, non-tuberculous mycobacteria, γδ T cells, IL-17A, interferon-gamma, granzyme B, TLR2, IL-1β, IL-23, pulmonary infection, immunology, antibiotic resistance